187 related articles for article (PubMed ID: 15275717)
1. Efficacy of I131 ablation therapy using different doses as determined by postoperative thyroid scan uptake in patients with differentiated thyroid cancer.
Zidan J; Hefer E; Iosilevski G; Drumea K; Stein ME; Kuten A; Israel O
Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1330-6. PubMed ID: 15275717
[TBL] [Abstract][Full Text] [Related]
2. Assessment of the efficacy of iodine-131 for thyroid ablation.
Comtois R; Thériault C; Del Vecchio P
J Nucl Med; 1993 Nov; 34(11):1927-30. PubMed ID: 8229236
[TBL] [Abstract][Full Text] [Related]
3. Incidence of radiation thyroiditis and thyroid remnant ablation success rates following 1110 MBq (30 mCi) and 3700 MBq (100 mCi) post-surgical 131I ablation therapy for differentiated thyroid carcinoma.
Cherk MH; Kalff V; Yap KS; Bailey M; Topliss D; Kelly MJ
Clin Endocrinol (Oxf); 2008 Dec; 69(6):957-62. PubMed ID: 18419785
[TBL] [Abstract][Full Text] [Related]
4. Prospective randomized clinical trial to evaluate the optimal dose of 131 I for remnant ablation in patients with differentiated thyroid carcinoma.
Bal C; Padhy AK; Jana S; Pant GS; Basu AK
Cancer; 1996 Jun; 77(12):2574-80. PubMed ID: 8640708
[TBL] [Abstract][Full Text] [Related]
5. Radioiodine dose for remnant ablation in differentiated thyroid carcinoma: a randomized clinical trial in 509 patients.
Bal CS; Kumar A; Pant GS
J Clin Endocrinol Metab; 2004 Apr; 89(4):1666-73. PubMed ID: 15070929
[TBL] [Abstract][Full Text] [Related]
6. Cumulative doses of adjunct 131I treatment depend on location of residual thyroid tissue after total thyroidectomy in differentiated thyroid cancer.
Saint-Vil D; Emran MA; Lambert R; Alos N; Turpin S; Huot C
J Pediatr Surg; 2007 May; 42(5):853-6. PubMed ID: 17502198
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors in well-differentiated thyroid carcinoma in patients treated and followed in the same institution.
Cappelli C; Pirola I; Braga M; De Martino E; Morassi ML; Gandossi E; Mattanza C; Balzano R; Castellano M; Rosei EA
Ann Ital Chir; 2006; 77(2):107-13. PubMed ID: 17147082
[TBL] [Abstract][Full Text] [Related]
8. Treatment for microcarcinoma of the thyroid--clinical experience.
Küçük NO; Tari P; Tokmak E; Aras G
Clin Nucl Med; 2007 Apr; 32(4):279-81. PubMed ID: 17413573
[TBL] [Abstract][Full Text] [Related]
9. [Early evaluation of treatment effectiveness using 131I iodine radiotherapy in patients with differentiated thyroid cancer].
Gawkowska-Suwińska M; Turska M; Roskosz J; Puch Z; Jurecka-Tuleja B; Handkiewicz-Junak D; Wygoda Z; Jarzab B
Wiad Lek; 2001; 54 Suppl 1():278-88. PubMed ID: 12182036
[TBL] [Abstract][Full Text] [Related]
10. Effects of different doses of radioactive iodine for remnant ablation on successful ablation and on long-term recurrences in patients with differentiated thyroid carcinoma.
Kim EY; Kim TY; Kim WG; Yim JH; Han JM; Ryu JS; Hong SJ; Yoon JH; Gong G; Kim WB; Shong YK
Nucl Med Commun; 2011 Oct; 32(10):954-9. PubMed ID: 21849927
[TBL] [Abstract][Full Text] [Related]
11. Salivary gland side effects commonly develop several weeks after initial radioactive iodine ablation.
Grewal RK; Larson SM; Pentlow CE; Pentlow KS; Gonen M; Qualey R; Natbony L; Tuttle RM
J Nucl Med; 2009 Oct; 50(10):1605-10. PubMed ID: 19759114
[TBL] [Abstract][Full Text] [Related]
12. Pregnancy outcome after diagnosis of differentiated thyroid carcinoma: no deleterious effect after radioactive iodine treatment.
Chow SM; Yau S; Lee SH; Leung WM; Law SC
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):992-1000. PubMed ID: 15234032
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic outcomes of papillary thyroid carcinomas with tumors more advanced than T1N0M0.
Lin JD; Lin KJ; Chao TC; Hseuh C; Tsang NM
Radiother Oncol; 2008 Oct; 89(1):97-104. PubMed ID: 18534700
[TBL] [Abstract][Full Text] [Related]
14. Radioactive iodine lobe ablation as an alternative to completion thyroidectomy for follicular carcinoma of the thyroid.
Randolph GW; Daniels GH
Thyroid; 2002 Nov; 12(11):989-96. PubMed ID: 12490076
[TBL] [Abstract][Full Text] [Related]
15. Lithium as adjuvant to radioiodine therapy in differentiated thyroid carcinoma: clinical and in vitro studies.
Liu YY; van der Pluijm G; Karperien M; Stokkel MP; Pereira AM; Morreau J; Kievit J; Romijn JA; Smit JW
Clin Endocrinol (Oxf); 2006 Jun; 64(6):617-24. PubMed ID: 16712662
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant external-beam radiotherapy in patients with high-risk well-differentiated thyroid cancer.
Chen PV; Osborne R; Ahn E; Avitia S; Juillard G
Ear Nose Throat J; 2009 Jul; 88(7):E01. PubMed ID: 19623515
[TBL] [Abstract][Full Text] [Related]
17. Patterns of relapse following radiotherapy for differentiated thyroid cancer: implication for target volume delineation.
Azrif M; Slevin NJ; Sykes AJ; Swindell R; Yap BK
Radiother Oncol; 2008 Oct; 89(1):105-13. PubMed ID: 18579244
[TBL] [Abstract][Full Text] [Related]
18. An analysis of "ablation of thyroid remnants" with I-131 in 511 patients from 1947-1984: experience at University of Michigan.
Beierwaltes WH; Rabbani R; Dmuchowski C; Lloyd RV; Eyre P; Mallette S
J Nucl Med; 1984 Dec; 25(12):1287-93. PubMed ID: 6502251
[TBL] [Abstract][Full Text] [Related]
19. Thyroid remnant ablation in patients with papillary cancer: a comparison of low, moderate, and high activities of radioiodine.
Kusacic Kuna S; Samardzic T; Tesic V; Medvedec M; Kuna K; Bracic I; Despot M; Dodig D
Nucl Med Commun; 2009 Apr; 30(4):263-9. PubMed ID: 19247212
[TBL] [Abstract][Full Text] [Related]
20. Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal.
Tuttle RM; Brokhin M; Omry G; Martorella AJ; Larson SM; Grewal RK; Fleisher M; Robbins RJ
J Nucl Med; 2008 May; 49(5):764-70. PubMed ID: 18413378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
